WARF: P00282US

Method of Targeting Pharmaceuticals to Motor Neurons


Eric Johnson, Michael Goodnough, William Tepp, Carl Malizio

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method for delivering therapeutic drugs to motor neurons.
OVERVIEWEven though therapeutic compounds have been developed for nervous system disorders, these conditions remain difficult to treat, largely because of the difficulties associated with delivering drugs to the nervous system. The therapeutics often are insoluble, have short half lives in the blood stream or have high systemic toxicity.
THE INVENTIONUW-Madison researchers have developed a method for delivering therapeutic drugs to motor neurons. This method could be used to treat botulism, which is caused by botulinum neurotoxin, a potentially serious biological warfare agent. It involves synthesizing a therapeutic molecule covalently bound to a polymeric delivery vehicle and conjugating it to a botulinum neurotoxin heavy chain. The botulinum neurotoxin heavy chain acts as a vehicle for delivery of pharmaceuticals to motor neurons.
  • Targeting molecules to motor neurons
  • Treating diseases such as botulism, Lou Gehrig's disease or multiple sclerosis
  • Capable of treating botulism by delivering an antagonist of botulinum neurotoxin to motor neurons
  • Holds tremendous potential to cure conditions such as Lou Gehrig’s disease and multiple sclerosis via enhanced drug delivery to motor neurons
For More Information About the Inventors
Contact Information
For current licensing status, please contact Andy DeTienne at or 608-960-9857.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.